“One reason [the role of radiation has expanded] is the accuracy and precision of treatment, irrespective of a patient’s mutational profile. Radiation, irrespective of that heterogeneity and those mutations, has a high probability of killing those cancer cells,” said Daniel Spratt, MD.
“Sexual wellness is critical to overall health and happiness. That’s why you see more men and women turning to specialty health clinics for solutions to problems they consider more aesthetic versus medical,” said Mitchell Hollander, MD.
Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
AI scribe solutions are one of the easiest technologies to deploy into existing workflows, writes Vadim Khazan.
"Cross-examination offers the other side the opportunity to poke holes in the witness’s story contemporaneously, helping the jury evaluate the credibility of the witness in real time," writes Kenton H. Steele, Esq.
"ctDNA holds a unique position as it offers a molecular means to quantify the extent of residual disease burden," says Adanma Ayanambakkam, MD.
Combining the antibody-drug conjugates sacituzumab govitecan and enfortumab vedotin was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.
“It was interesting to find that when Black and White men were provided equal access to the same therapies, given at the same dosage and monitored in the same setting, disparities in outcomes were eliminated," says Jun Gong, MD.
The application is based on results from the phase 3 CheckMate-901 trial.
Novartis is now equipped to provide 177Lu-PSMA-617 to patients within 2 weeks of diagnosis with advanced disease.
"If a patient begins treatment with platinum-based chemotherapy and maintenance immune checkpoint inhibition, second-line options may involve evaluating erdafitinib, ADCs, or participation in clinical trials," says Adanma Ayanambakkam, MD.
The FDA’s Fast Track designation is designed to expedite the review and development of novel treatments that will fill an unmet medical need.
The combination of oral masofaniten (formerly EPI-7386) and enzalutamide was well tolerated and elicited durable reductions in PSA levels in patients with metastatic castration-resistant prostate cancer.
The primary end point of the phase 3 CLARIFY trial is the diagnostic capability of 64Cu-SAR-bisPSMA PET to identify regional node metastases.
Patients were nearly twice as likely to develop urinary symptoms and urinary frequency when their prostatic urethra was greater than 4.6 cm in length.
At the time of data cutoff, 16 patients in cohort 1 and 27 patients in cohort 3 had been treated with TAR-210, an intravesical delivery system for erdafitinib.
The FDA has accepted a resubmitted biologics license application for N-803 for use in combination with BCG for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
ARX517, a PSMA-targeting antibody-drug conjugate, demonstrated favorable efficacy and safety in a phase 1/2 trial in patients with metastatic castration-resistant prostate cancer.
Using a case-based, interactive approach, this course is designed to offer practical clinical and surgical pearls for the management of women with complex pelvic floor disorders and complications.
Data showed a 20% reduced risk of recurrence or death among patients who received everolimus compared with placebo.
“Relugolix is the first approved ADT in Canada that can be administered orally, and once daily, offering a safe and effective option for advanced prostate cancer patients in the country," said Fred Saad, MD.
“There’s a 72% less chance of recurrence with oral erdafitinib than with standard of care. The problem is tolerability,” says James W.F. Catto, PhD, FRCS.
Treatment with the intravesical chemotherapy delivery system TAR-200 led to complete responses in over three-fourths of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.
“As private equity firms increasingly engage in urology, key stakeholders, including policymakers and urologists, need to ensure that the quality of care is not compromised with the structural changes implemented after acquisition," write the authors.
“No doubt about it, this is unequivocally a positive trial by the rPFS criteria. Quite positive,” says A. Oliver Sartor, MD.
A post hoc analysis from the phase 3 CLEAR trial showed that frontline lenvatinib plus pembrolizumab elicited improved tumor response vs sunitinib across subgroups of patients with clear cell renal cell carcinoma.
“This is the first time [in urothelial carcinoma] we've managed to beat chemotherapy in the first-line setting for overall survival,” said Thomas B. Powles, MBBS, MRCP, MD.
Frontline therapy with nivolumab plus gemcitabine-cisplatin, followed by nivolumab maintenance, led to improved overall and progress-free survival in patients with unresectable or metastatic urothelial carcinoma.
Adding niraparib to abiraterone acetate and prednisone (AAP) was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
“Belzutifan demonstrated a significant improvement in PFS with a hazard ratio of .75, and a significant P value. Similar findings were noted at the second interim analysis with a hazard ratio of .74,” says Laurence Albiges, MD, PhD.
